Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Illumina Laboratory Services, |
RCV000375914 | SCV000403692 | uncertain significance | Progressive myoclonic epilepsy | 2016-06-14 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000375914 | SCV000952751 | uncertain significance | Progressive myoclonic epilepsy | 2022-08-23 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be tolerated. ClinVar contains an entry for this variant (Variation ID: 323826). This variant has not been reported in the literature in individuals affected with GOSR2-related conditions. This variant is present in population databases (rs772342696, gnomAD 0.004%). This sequence change replaces leucine, which is neutral and non-polar, with valine, which is neutral and non-polar, at codon 181 of the GOSR2 protein (p.Leu181Val). |
Gene |
RCV001575029 | SCV001801939 | uncertain significance | not provided | 2019-04-09 | criteria provided, single submitter | clinical testing | Not observed at a significant frequency in large population cohorts (Lek et al., 2016); In silico analysis, which includes protein predictors and evolutionary conservation, supports that this variant does not alter protein structure/function; Has not been previously published as pathogenic or benign to our knowledge |